<DOC>
	<DOCNO>NCT00421447</DOCNO>
	<brief_summary>The primary objective study determine trabecular cortical volumetric bone mineral density ( vBMD ) change time postmenopausal breast cancer patient prescribed Anastrozole , measure pQCT proximal distal radius tibia .</brief_summary>
	<brief_title>Bone Geometry Muscle Density Changes Postmenopausal Women Breast Cancer Patients Prescribed Anastrozole</brief_title>
	<detailed_description>In bone , estrogen require maintain density , indication increase turnover patient prescribed Aromatase Inhibitors . However , study date prospectively quantify impact Aromatase inhibitor bone quality . Furthermore , actual effect clinical significance adjuvant chemotherapy supportive medication bone quality woman breast carcinoma unknown . The current study propose prospectively assess novel skeletal health outcome , namely trabecular structure ( connectivity , hole size ) bone geometry ( bone area , cortical thickness ) among woman breast cancer treat Anastrozole . Not current study provide good understanding change bone quality muscle mass Anastrozole treatment , provide important information development secondary skeletal complication population . Therefore , potential collect data prospectively cohort individual breast cancer treat Anastrozole represent important step advance knowledge area . Also , examine bone quality secondary complication diverse cohort patient vary respect radiation therapy , chemotherapy additional medication , begin identify patterns musculoskeletal change predictor change .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>Group 1 : Treatment Group Postmenopausal breast cancer patient ( stage 1 2 ) Noninstitutionalized Prescribed Anastrozole within precede 12 week Ambulatory Ability read comprehend study protocol inform consent Group 2 : Control Group Healthy , agematched postmenopausal woman Noninstitutionalized Ambulatory Ability read comprehend study protocol inform consent Prior Tamoxifen Raloxifene therapy Known congenital metabolic bone disease ( e.g. , osteogenesis imperfecta ) Concomitant treatment corticosteroid Patients history endocrine disorder surgical parathyroidectomy Patients disorder know affect bone metabolism include diabetes mellitus , systemic lupus erythematosus , Cushing 's disease , hyperparathyroidism , chronic liver disease , chronic renal failure , Paget 's disease Conditions prevent pQCT measurement ( e.g. , unable lie flat still 15 minute ) Geographically inaccessible followup</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>pQCT</keyword>
	<keyword>Anastrozole</keyword>
	<keyword>bone geometry</keyword>
</DOC>